What is Prothrombin Time (PT)?
Prothrombin time (PT) is a laboratory test that measures the time it takes for blood plasma to clot after adding tissue factor (thromboplastin) and calcium, reported in seconds. 1
Core Definition and Measurement
PT is scientifically known as "tissue factor-induced coagulation time" and measures how long it takes for a stable clot to form in citrated plasma after adding thromboplastin reagent and calcium chloride 1, 2. The test is performed using an in vitro diagnostic medical device that includes:
- A thromboplastin reagent (tissue factor from human, bovine, or rabbit sources)
- A technique or instrument to determine the clotting endpoint
- Measurement recorded in seconds 1
The actual PT result depends heavily on which thromboplastin reagent and measurement technique are used, which is why standardization through the International Normalized Ratio (INR) became necessary 1, 3.
Primary Clinical Purpose
PT was specifically designed and validated for monitoring vitamin K antagonist (VKA) therapy, particularly warfarin 3. The test assesses the extrinsic and common coagulation pathways, evaluating factors II, V, VII, X, and fibrinogen 4.
Key Clinical Applications:
- Monitoring oral anticoagulation therapy with warfarin and other VKAs 1, 5
- Assessing coagulation status in patients on stable VKA therapy 3
- Converting to INR using the formula: INR = (PT/MNPT)^ISI where MNPT is mean normal prothrombin time and ISI is international sensitivity index 1
Critical Limitations and Misuse
The PT/INR was validated only for patients on VKA therapy and lacks evidence for other clinical applications 3. Despite this narrow validation:
- PT/INR is widely misused as a general coagulopathy screen 3
- It is not validated for predicting bleeding risk in patients not on VKAs 3
- INR targets are poor predictors of bleeding in liver disease and acute illness 3
- The test only measures procoagulants, failing to capture anticoagulant changes (particularly relevant in cirrhosis) 6
Common Pitfalls:
- False prolongation can occur with polycythemia/erythrocytosis due to excess citrate in the sample 4
- Results vary significantly between laboratories even with identical samples due to different thromboplastin sources 3, 7
- Misinterpretation leads to unnecessary plasma transfusions for mildly elevated INRs (1.0-2.0 range) without evidence of benefit 3
Standardization Context
The INR system was developed to standardize PT results across different thromboplastins and minimize inter-laboratory variability, specifically for warfarin monitoring 1, 3. This standardization relies on comparing clotting times from patients on stable VKA therapy, excluding those with bleeding disorders, acute illness, liver disease, or other anticoagulants 3.
Bottom line: PT measures clotting time in seconds and should primarily be used for VKA monitoring when converted to INR—its use outside this context lacks validation and can lead to harmful interventions.